Gordion Bioscience

Gordon Bioscience

biotech / health AI / medtech (cancer therapeutics)

Visit website

StageSeed

Raised$120K

Founded2023

Employees6

LocationBoston, MA

ValuationNot publicly disclosed

About

Gordion Bioscience has built a proprietary patient-derived dependency map across 20,000 genes and 26 cancer types - translating real tumor biology into pipeline decisions.Standard preclinical models (CRISPR screens, cell lines) systematically misrepresent the dependencies operating in patient tumors. Gordion's map is built entirely from tumor biopsies, revealing what tumors actually depend on in human disease. Platform applications: - Target validation, distinguishing clinically translatable targets from cell-line artifacts. - Combination strategy — identifying co-dependencies that limit monotherapy response (KRAS programs being a prime example). - Bispecific design — functional co-dependency data from patient tumors, not inferred cell line biology. Traction: Novel target against MTAP-mutated solid tumors licensed to Kohde Pharma (2025); first IO bispecific outlicensed (2026). Proprietary portfolio: currently focusing on building a portfolio of Bi and Tri-specific antibodies for PDAC, CRC and NSCLC.

Product

Value proposition: Building multispecific antibody therapies and combinations for genetically defined cancer patient populations; a platform that identifies synergistic target pairs in real patient tumor data and advances them towards clinical development.
Target customers: pharmaceutical companies, biotech researchers, clinical development teams

Founders

Pawel Zawadzki
Kasia Zawadzka
Pawel Sztromwasser
Thomas Wirth
Francois Aymard

Products

multispecific antibody therapiestarget identification platformcohort/selective targeting pipeline

Key features

identify synergistic target pairs from real patient tumor dataintegrates genomic, transcriptomic, and clinical datacohort selection integrated with target identificationpipeline advances candidates toward clinical developmentuses patient biopsy data (not cell lines)covers ~26 cancer types

Technologies

AIgenomicstranscriptomicsclinical data integrationbiotech pipelinemultispecific antibodies

Integrations

EHRs / clinical data platforms

Target conditions

canceroncologygenetically defined cancer populations

Care settings

research laboratoryclinical developmentbiotech startup

Investors

TechstarsCreative Destruction LabUniversity of Toronto

News

Gordian Biotechnology - Crunchbase Company Profile & Funding · 2025-11-02T00:00:00.000Z
Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies - BioSpace · 2026-05-26T14:52:52.000Z
Gordian Biotechnology 2026 Company Profile - PitchBook · 2025-06-01T00:00:00.000Z
Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity · 2026-01-08T13:00:00.000Z
Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies | Morningstar · 2026-05-26T12:00:00.000Z
Drug Discovery: Don’t just add AI - Gordian Biotechnology · 2024-11-20T13:25:02.000Z

Browse similar startups

Related startups

Hampshire Dermatology and Skin Health Center — Northampton, MA
Haver AI Inc. — Cambridge, MA
HOLYOKE PEDIATRIC ASSOCIATES, LLP — Holyoke, MA
HUED Mamas Co. — Boston, MA
Intellegi™ — Cambridge, MA
INVIZA® Health—Powering Remote Monitoring via Wearable Edge AI™ — Cambridge, MA
Helicore Biopharma — San Mateo, CA
ImmunoMetabolix — Bridgewater, NJ
ImYoo — Mountain View, CA
Liberate Bio — Boston, MA
Metanoia Bio Inc. — los angeles, CA
nChroma Bio — Boston, MA

Profile updated Jul 29, 2026. Sources: gordion.bio